SCHEDULE 13G/A: T. Rowe Price Associates Discloses 12.7% Stake in Repligen Corp

T. Rowe Price Associates, Inc. has reported a 12.7% beneficial ownership stake in Repligen Corp, holding over 7.1 million shares as of December 31, 2024.

Summary

• T. Rowe Price Associates, Inc. filed an Amendment No. 5 to Schedule 13G regarding its beneficial ownership of common stock in Repligen Corp.
• As of December 31, 2024, T. Rowe Price Associates, Inc. beneficially owned an aggregate of 7,136,086 shares of Repligen Corp's common stock.
• This ownership represents 12.7% of the class of securities.
• T. Rowe Price Associates, Inc. holds sole voting power over 6,445,000 shares and sole dispositive power over 7,136,086 shares.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Repligen Corp.

Sentiment

Score: 7

Explanation: The filing indicates a significant and stable institutional investment by T. Rowe Price Associates, Inc. in Repligen Corp, suggesting continued confidence from a major investor. There are no negative disclosures or indications of intent to influence control, which is generally viewed positively by the market.

Positives

• T. Rowe Price Associates, Inc., a prominent investment adviser, maintains a significant 12.7% beneficial ownership stake in Repligen Corp, indicating continued substantial institutional investment.

Risks

• T. Rowe Price Associates, Inc. explicitly states that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied (a standard legal disclaimer).

Future Outlook

NA

Management Comments

• T. Rowe Price Associates, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

The filing reflects a standard institutional investment by T. Rowe Price Associates, Inc., a major investment management firm, in a publicly traded company within the biotechnology or life sciences sector, which is common practice for large asset managers.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially reinforcing confidence in the company's long-term prospects.
• Management: Awareness of a large, passive institutional investor holding a substantial portion of the company's shares.

Key Dates

Recommendation

Keywords

Repligen Corp, T. Rowe Price Associates, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, investment adviser